Hesham R Omar,Ehab El-Khabiry,Susan Vaughan
Hesham R Omar
Diabetes treatment in 2025: can scientific advances keep pace with prevalence? [0.03%]
2025年的糖尿病治疗：科学进步能否跟上流行趋势？
Mansur Shomali
Mansur Shomali
Despite the known benefits of a healthy lifestyle, many individuals find it hard to maintain such a lifestyle in our modern world, which facilitates sedentary behavior and overeating. As a consequence, the prevalence of type 2 diabetes mell...
Evangelos Papanastasiou
Evangelos Papanastasiou
The metabolic syndrome (MetS) is an increasingly prevalent condition in people with schizophrenia. It remains highly prevalent in the general population in developed countries, but recently health promotion campaigns and greater awareness o...
Hesham R Omar,Irina Komarova,Mohamed El-Ghonemi et al.
Hesham R Omar et al.
Licorice extract has always been recognized as a sweetener and a thirst quencher. Its nutritive value is overrated by many who consume significant amounts and are prone to complications. Glycyrrhetic acid, the active metabolite in licorice,...
Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials [0.03%]
利格列汀治疗二型糖尿病：关键临床试验述评
Janet B McGill
Janet B McGill
Patients with type 2 diabetes mellitus (T2DM) frequently require multiple therapies to effectively control hyperglycemia, and many new agents for glucose control have been developed over the past few decades. Linagliptin is a recently appro...
Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes [0.03%]
预混门冬胰岛素30治疗对中国2型糖尿病患者的有效性和安全性研究：一项随机、双盲、平行对照的临床试验
Dario Giugliano,Katherine Esposito
Dario Giugliano
The three currently marketed long-acting insulin analogs, glargine, detemir and insulin lispro protamine suspension (ILPS), represent the most significant advances in basal insulin supplementation since the 1940s and 1950s and the introduct...
Jens Jordan,Sam W Boye,Stephanie Le Breton et al.
Jens Jordan et al.
Background: Even though patients with class 3 obesity (body mass index ≥ 40 kg/m(2)) are prone to arterial hypertension and respond less to antihypertensive drugs, they are not considered in hypertension treatment guidel...
Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) for the treatment of adult patients with growth hormone deficiency [0.03%]
成人PATRO研究的设计与立题：一项关于生长激素缺乏症成人患者奥曲肽治疗长期安全性和有效性的多中心非干预性研究
Paolo Beck-Peccoz,Francesco Minuto,Alfonso Leal-Cerro et al.
Paolo Beck-Peccoz et al.
Objective: To describe the rationale and design of PATRO Adults, a postmarketing surveillance study of the long-term efficacy and safety of somatropin (Omnitrope(®)) for the treatment of adult patients with growth hormon...
Stefan Engeli
Stefan Engeli